Bioventus (BVS) Osake Kurssi

Bioventus Inc is a leading healthcare company specializing in orthobiologic solutions. The business model of Bioventus is centered around the development, manufacturing, and marketing of innovative and clinically proven products for musculoskeletal healing and rehabilitation. The company focuses on providing non-invasive and cost-effective treatments for conditions such as osteoarthritis, surgical and non-surgical bone healing, as well as sports medicine and spine disorders. Bioventus aims to improve patient outcomes through its advanced biologics and medical devices, partnering with healthcare professionals worldwide. With its dedication to research, development, and customer-centric approach, Bioventus continues to establish itself as a prominent player in the orthobiologics industry.

Bioventus Inc is primarily active in the healthcare industry.

Bioventus Inc is a renowned global healthcare company specializing in orthobiologics and surgical solutions. Founded in 2012, Bioventus has grown into a leading player in the field, with a focus on delivering innovative and cost-effective healthcare solutions. With a strong emphasis on research and development, Bioventus strives to provide cutting-edge products to improve patient outcomes. The company's history showcases a commitment to collaboration with industry experts and medical professionals to address unmet clinical needs. Bioventus Inc continues to expand its product portfolio and enhance its presence in the medical community, making significant contributions to the healthcare sector.

Bioventus Inc has achieved significant milestones since its inception. The company has successfully introduced innovative orthobiologic solutions to enhance patient outcomes and improve musculoskeletal health. They have made remarkable advancements in the field of orthopedics, offering novel treatment options for conditions like osteoarthritis and joint pain. With a strong focus on research and development, Bioventus has secured numerous patents and collaborations, solidifying their position as a leader in orthobiologics. The company has also expanded its global presence, reaching patients in over 70 countries. These milestones reflect Bioventus Inc's dedication to revolutionizing orthopedic care and improving the quality of life for individuals worldwide.

Bioventus Inc is primarily present in various countries and regions around the world. These include the United States, United Kingdom, Germany, France, Italy, Spain, Australia, and Canada, among others.

Bioventus Inc represents the values of innovation, patient-centricity, and collaboration. With a corporate philosophy focused on improving patient outcomes and quality of life, Bioventus is dedicated to developing and commercializing innovative solutions for musculoskeletal healing and management. Through its strong commitment to research and development, Bioventus aims to provide cutting-edge products and therapies to address unmet medical needs. The company prioritizes collaboration with healthcare professionals, patients, and other stakeholders to drive advancements in regenerative medicine and orthobiologics. Bioventus Inc's dedication to excellence and its patient-focused approach make it a leading player in the musculoskeletal healthcare industry.

Analyytikot asettavat tällä hetkellä Bioventus-osakkeelle keskimääräisen tavoitehinnan 18,33 USD (mediaani: 18,00 USD), mikä merkitsee +32,0 % viimeisimpään hintaan verrattuna. Konsensus perustuu 9 analyytikkoarvioon.

Bioventus Analyytikkojen kursstavoitteet 2026

9 analyytikkoa arvioi tällä hetkellä Bioventus-osaketta: 8 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Bioventus-yhtiöltä 604,79 M USD liikevaihtoa ja 0,73 USD osakekohtaista tulosta.

Bioventus Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Bioventus-osake noteerataan hintaan 12,38 EUR (13,89 USD).

Bioventus-osake (BVS) on listattuna 1 pörssissä, muun muassa: NASDAQ (BVS).

Bioventus Inc. is a global medical technology company specializing in orthopedic biologics. The company is headquartered in Durham, North Carolina and employs over 700 people worldwide. Bioventus focuses on the development, manufacturing, and marketing of biologics for orthopedic healing processes, as well as the development and delivery of innovative orthopedic products. The business model of Bioventus encompasses two main areas: orthobiologics and extremity healing-based products. Orthobiologics refers to biological materials or substances that are either derived from the body's own tissue or synthetic materials. Extremity healing-based products are products specifically designed for the treatment of extremities and joints. Bioventus focuses on the development of biologics that contribute to bone and soft tissue growth stimulation. The company's product offerings include synthetic bone replacement materials, Bio-TENODESIS screws, OP-1 implant systems, and TRUFUSE spinal solutions. Cartilage regeneration is another important area in science and medicine, and Bioventus offers a variety of products that support this healing process. The PRIMATRIX gel matrix is a biodegradable, strand-shaped membrane made from a collagen suspension and is used for cartilage repair. The GENUTRAIN series offers surgical orthopedic accessories for the treatment of knee or elbow joint conditions. Bioventus also has a significant presence in the wound management field. Using its proprietary PRO-STAT technology, the company has developed an excellent portfolio of wound management products, including Soluble Hemostat and Exapline Wound Matrix. The products in this line are used in hospitals and clinics worldwide to assist patients in wound healing and infection control. Overall, Bioventus' business model is focused on improving the rehabilitation process for patients. The combination of orthobiologics, extremity healing-based products, and wound management products provides a holistic solution for enhancing the healing process. Through collaboration with leading medical experts and researchers, the company is always striving to maximize the potential of its products and promote patient healing worldwide.

odotettu liikevaihto Bioventus on 604,79 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Bioventus on 50,27 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Bioventus:n hinta-voitto-suhde (P/E) on tällä hetkellä 19,04. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Bioventus-osakkeen arvostusta.

Bioventus:n hinta-myynti-suhde (P/S) on tällä hetkellä 1,58. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Bioventus-osakkeen arvostuskennuslukuna.

Bioventus:n Eulpool-laatuscore on 4/10.

Bioventus:n ISIN on US09075A1088. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Bioventus:n ticker on BVS. Tämä pörssinoteeraus käytetään Bioventus-osakkeiden kauppaan pörssissä.